Gabapentin Oral Rinse Dosing for Swish-and-Spit
Use gabapentin 250 mg/mL solution for swish-and-spit administration in oral pain conditions like burning mouth syndrome. This concentration has demonstrated clinical effectiveness and tolerability in retrospective studies 1.
Recommended Dosing Protocol
The evidence supports the following approach:
- Concentration: 250 mg/mL gabapentin solution
- Administration: Swish and spit (do not swallow)
- Frequency: As needed for symptom control, typically multiple times daily
Evidence Base
The strongest clinical evidence for topical gabapentin oral rinse comes from a 2023 retrospective study evaluating 19 patients with burning mouth syndrome 1. This study used gabapentin 250 mg/mL solution administered as a swish-and-spit formulation. Patients reported a median 2-point reduction in burning pain on a 0-10 numeric rating scale (p < 0.01) at median follow-up of 86 days. Adverse drug reactions occurred in only 15.8% of patients, demonstrating good tolerability 1.
The 2025 expert consensus guideline on radiochemotherapy-induced oral mucositis discusses various topical analgesics for oral pain but does not specifically address gabapentin oral rinses 2. However, it establishes the precedent for topical analgesic rinses, noting that doxepin oral rinse (5 mg/mL) can be used for 1 minute, followed by spitting, 3-6 times daily 2.
Important Caveats
This is off-label use: The FDA-approved gabapentin formulations are for systemic oral administration, not topical oral rinse 3. Standard FDA dosing (300-3600 mg/day orally in divided doses) does not apply to swish-and-spit administration 3.
Limited evidence: Only one small retrospective study specifically evaluates this formulation and route 1. Larger prospective randomized trials are needed.
Compounding required: The 250 mg/mL concentration requires pharmacy compounding, as it is not commercially available.
Monitor for systemic absorption: Although designed for topical use, some systemic absorption may occur. Watch for typical gabapentin side effects (dizziness, somnolence) 3.